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Superpotent topical corticosteroids (CS) have been demonstrated to improve bullous pemphigoid (BP) patients’survival. We assessed
whether amild regimen using lower doses of topical CS and a shorter duration could improve the outcome of BP patients evenmore.
Three-hundred and twelve BP patients were included in a multicenter randomized controlled trial and stratified depending on the
extent of BP as moderate (n¼ 134) or extensive (n¼ 178). Patients were randomly assigned to the standard regimen (clobetasol
propionate cream, 40g per day initially, with CS tapering over 12 months) or the mild regimen (10–30g per day), with CS tapering over
4 months. A noninferior rate of BP control was obtained with the mild regimen 156/159 (98%) as compared with the standard regimen
150/150 (100%; P¼ 0.005). Event-free survival, that is, the combined outcome of deaths and life-threatening adverse events did not
differ between the two treatment groups (P¼ 0.77). However, upon adjusting through the Cox model for age and Karnofsky score, a
strong beneficial effect of themild regimen was observed in patients with moderate BP, with an almost twofold decrease in the risk of
death or life-threatening adverse events relative to the standard regimen (hazard ratio¼ 0.54; 95% confidence interval, 0.30–0.97;
P¼ 0.039). This mild regimen allows a 70% reduction of the cumulative doses of CS and improves BP patients’ outcome.
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INTRODUCTION
Bullous pemphigoid (BP) is the most frequent autoimmune
blistering disease of the skin (Bernard et al., 1995;
Zillikens et al., 1995; Gudi et al., 2005; Baricault et al.,
2006; Langan et al., 2008). BP mainly affects the elderly (Jung
et al., 1999), with mean age of patients between 77 and 81
years in recent studies (Joly et al., 2002, 2005; Beissert et al.,
2007; Cordel et al., 2007). The incidence rate of BP is about
200 cases per million per year among subjects over 75 years
(Jung et al., 1999; Gudi et al., 2005). Importantly, a
significant proportion of these elderly BP patients are in poor
general condition, with a high prevalence of neurological
and cardiovascular disorders (Roujeau et al., 1998; Joly et al.,
2002, 2005; Rzany et al., 2002; Cordel et al., 2007). We
recently demonstrated that old age and poor general
condition are major deleterious prognostic factors of BP
patients (Joly et al., 2005).
Until recently, high doses of systemic corticosteroids (CS)
were considered the standard treatment for BP patients (Fine,
1995). Following two large retrospective studies in France
and Germany suggesting that such high doses of oral CS were
poorly tolerated in these elderly patients and were associated
with decreased survival (Roujeau et al., 1998; Rzany et al.,
2002), a large controlled clinical trial demonstrated that high
doses of superpotent topical CS increased survival of patients
with extensive BP, as compared with oral prednisone,
1mg kg1 per day (Joly et al., 2002). Moreover, topical CS
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were demonstrated to be more effective than oral prednisone,
as the rate of disease control obtained with topical treatment
was 100 and 99% in patients with moderate and extensive
BP, as compared with 95 and 91% with oral prednisone,
respectively.
However, local and systemic complications were ob-
served in patients treated with topical CS. Some of these
adverse events may have been favored by the high doses of
clobetasol propionate cream and the long duration of
treatment (12 months). To improve the regimen of topical
CS used to treat BP patients, we conducted a randomized trial
comparing this 12-month regimen using high initial doses of
topical CS, to a short-duration regimen of only 4 months,
using lower initial doses of clobetasol propionate cream. The
aim of this study was to assess whether this ‘‘mild’’ regimen
of topical CS could improve survival, decrease the frequency
of severe and life-threatening treatment side effects, while
providing a noninferior rate of disease control relative to the
‘‘standard’’ regimen.
RESULTS
Patients
Between January 2002 and December 2004, 335 patients
were assessed for eligibility. Informed consent could not be
obtained from four patients or their family in fourteen
patients with dementia. Previous use of medication
effective against BP (in five patients), diagnosis of another
autoimmune blistering skin disease (in three patients), and
immediate withdrawal of consent (in one patient) were
other reasons for exclusion. Of the remaining 312 patients,
134 had 10 or fewer new bullae daily (moderate disease)
and 178 had more than 10 new bullae daily (extensive
disease). Among the 134 patients with moderate disease, 69
were randomly assigned to receive the mild regimen and 65
the standard regimen of topical CS. Among the 178 patients
with extensive disease, 90 were randomly assigned to receive
the mild regimen and 88 to receive the standard regimen.
Of the 159 patients assigned to receive the mild regimen,
8 patients received an initial daily dose of clobetasol
propionate cream of 10 g, 64 patients received 20 g, and 87
received 30 g, based on their weight and extent of disease.
Baseline characteristics of the patients are shown in Table 1.
Among both patients with moderate BP and patients with
extensive BP, the groups of patients assigned to receive the
mild or the standard regimen of topical CS were well
balanced in terms of number of daily new bullae (33.9 vs
32.3; P¼0.83) and weight (68.3 vs 68.2 kg; P¼0.96).
However, patients assigned to receive the mild regimen
were older than those receiving the standard regimen (83.3 vs
80.8 years; P¼0.02) and had a somewhat lower Karnofsky
score (60.8 vs 64.6%, P¼ 0.83). Of the 312 patients, 3
included were lost to follow-up early after the initiation of
treatment and were not available for the evaluation of
efficacy by day 21 and were not included in the event-free
survival analysis (Figure 1). The median duration of follow-up
among surviving patients was 365 days (interquartile range:
363–365 days).
Disease control and survival
Among the 309 patients available for treatment efficacy by
day 21, control of disease was achieved in all the 150
patients who were assigned to the standard regimen (100%;
95% confidence interval (CI), 98–100%) and in 156 of the
159 patients who were assigned to the mild regimen (68 of 69
patients with moderate BP and 88 of 90 with extensive BP;
98%; 95% CI, 95–100%; P¼0.005) showing noninferiority of
the mild regimen according to the prespecified 0.05
noninferiority range (Table 2).
A total of 118 patients died during the 1-year follow-up;
40 of these had moderate BP, and 78 had extensive BP. The
causes of death were determined in 93 cases (79%); the main
causes were deterioration of patients’ general condition in 32
cases, sepsis in 29 patients (including 23 patients with
pneumonia), cardiovascular diseases in 5 patients, and stroke
in 6 patients.
Among the patients with moderate BP, 19 patients (28%)
in the mild treatment group, and 21 (33%) in the standard
treatment group died. Among the patients with extensive BP,
Table 1. Baseline characteristics of the patients
Moderate disease (p10 new bullae per day) Extensive disease (410 new bullae per day)
Characteristics of the patients Standard regimen (n=65) Mild regimen (n=69) Standard regimen (n=88) Mild regimen (n=90)
Age (years) 81.5±8.4 84.8±8.6 80.2±12.2 82.2±8.3
Sex (no)
Male 28 25 37 39
Female 37 44 51 51
Karnofsky score (%) 68.3±23.6 60.1±22.4 61.9±22.9 61.2±22.1
Weight (kgs) 68.0±14.1 65.9±16.1 68.5±16.4 70.0±18.5
Number of new bullae daily 4.9±10.3 6.0±9.9 52.6±91.5 55.2±70.3
For all variables except sex, mean value±SD is reported.
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41 patients (45%) in the mild regimen group, and 37 patients
(42%) in the standard regimen group died. The 1-year
Kaplan–Meier overall survival rate was 62% (95% CI,
55–70%) in the group of patients treated with the mild
regimen, and 61% (95% CI, 54–69%) in patients treated with
the standard regimen (P¼0.77, log-rank test). Forty-two life-
threatening adverse events were observed in 33 patients.
Comparison of Kaplan–Meier event-free survival curves
taking into account both deaths and life-threatening adverse
events did not reveal any difference between the two
treatment groups (P¼0.95; Figure 2a). After adjusting
through the Cox regression model for the two major
prognostic factors, age, and the Karnofsky score, a strong
beneficial effect of the mild regimen was evidenced in
patients with moderate disease with a hazard ratio of death of
0.52 (95% CI, 0.27–0.98; P¼0.044) for patients treated with
the mild regimen, and a hazard ratio of combined death or
life-threatening side effect occurrence of 0.54 (95% CI,
0.30–0.97; P¼0.03) for patients treated with the mild
regimen, as compared with those treated with the standard
regimen. In contrast, no effect of the treatment regimen on
overall or event-free survival was evidenced in patients with
extensive BP (hazard ratio¼ 1.18; 95% CI, 0.76–1.82;
P¼0.46 for overall survival).
Time to disease control and relapses
Mean time to achieve disease control was 7.9±2.6 days in
the 150 patients who were allocated to the standard regimen,
and 8.2±3.1 days in the 156 patients allocated to the mild
regimen who experienced disease control (P¼0.56; Table 2).
A total of 52 out of the 150 patients in the standard treatment
regimen group (35%; 95% CI, 27–43%) and 67 of the 156
patients in the mild regimen group (43%; 95% CI, 35–51%)
experienced at least one relapse during the follow-up after
median time of 149 and 140 days for the first relapse,
respectively. Kaplan–Meier disease-free survival curves
showed a higher rate of relapse in patients allocated to
receive the mild regimen (especially after treatment with-
drawal by day 120), as compared with patients allocated to
receive the standard regimen (which lasted 12 months), with
Assessed for eligibility (n=335)
Excluded (n=23) 
• Not meeting inclusion criteria (n=3)
• Refused to participate (n=14)
•
•
•
Immediate withdrawal of consent
(n=1) 
Previous use of medication
effective against BP (n=5)
Randomized (n =312) 
Allocated to the mild regimen Allocated to the standard
regimen  
(n=159)
Received allocated intervention
(n=159)
(n=153)
Received allocated intervention
(n=153) 
Lost to follow-up (n=0)
Lost to follow-up (n=3)Discontinued intervention (n=3)
Discontinued intervention (n=0)Follow-up
Unsatisfactory therapeutic effect (n=3) 
Analyzed (n=159) Analyzed (n=150) 
(intent to treat population) (intent to treat population)    Analysis 
Excluded from analysis (n=0) Excluded from analysis (n=0)
Allocation
Figure 1. Flow chart of the study.
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1-year disease-free survival rates of 30 and 45%, respectively
(P¼0.012; Figure 2b).
Treatment adverse effects and cumulative doses of treatment
Overall, 421 severe side effects were reported in 178
patients, with 227 severe side effects reported in 89 patients
from the standard regimen group (2.55 severe side effects per
patient), and 194 in 89 patients from the mild regimen group
(2.18 severe side effects per patient; P¼ 0.045; Table 2).
Main severe side effects in the standard and mild regimen
groups were diabetes mellitus in 34 and 18 patients
(P¼0.025), cardiovascular and neurovascular disorders in
35 and 21 patients (P¼0.034), and severe infections in 32
and 27 patients (P¼0.57), respectively. Main cutaneous side
effects were purpura, which was reported in 39 and 31%,
severe skin atrophy in 10 and 8%, and striae in 3 and 2% of
patients treated with the standard regimen and the mild
regimen, respectively. The median cumulative dose of
clobetasol propionate cream applied during the study
(including additional treatment in relapsing patients) was
71% lower in the mild regimen group (825 g with range
75–2,880 g) than in the standard regimen group (2,880 g with
range 600–6,960 g; Po104).
Hypothalamo–pituitary–adrenal axis suppression testing
Hypothalamo–pituitary–adrenal axis suppression tests were
performed in a subgroup of 28 BP patients recruited in one
center who received a daily dose of clobetasol propionate of
20 g (n¼9), 30 g (n¼9), or 40 g (n¼10). Plasma cortisol levels
measured at day 0 were within the normal range
(250–850nmol l1) in all cases. A positive response to the
administration of Cosyntropin was observed at day 0 in all but
one case. A positive response to the Cosyntropin test was
observed on days 7 and 30 in 5 of 18 (28%) and 4 of 16 (25%)
patients treated with the mild regimen and in 1 of 8 (12%) and
2 of 10 (20%) patients treated with the standard regimen.
DISCUSSION
This study confirmed the extremely high efficacy of topical
CS in the treatment of BP, as the rates of disease control
obtained with the mild and standard regimens used in this
study (98 and 100%, respectively) were almost identical to
those obtained in our initial controlled trial, which tested the
standard regimen (99% of control in extensive BP and 100%
in moderate BP; Joly et al., 2002). These findings confirm that
superpotent topical CS are the most effective treatment for
patients with BP, including those with an extensive disease,
limiting at least initially the need for immunosuppressive
drugs, which are poorly tolerated in these elderly patients
(Krain et al., 1972; Burton et al., 1978; Thivolet et al., 1985;
Guillaume et al., 1993; Paul et al., 1994; Bohm et al., 1997;
Table 2. Main outcomes of the study depending on the extent of BP and treatment regimens
Moderate disease p10 new bullae per day Extensive disease 410 new bullae per day
Mild regimen (n=69) Standard regimen (n=65) Mild regimen (n=90) Standard regimen (n=88)
Number of events (%) Number of events (%) Number of events (%) Number of events (%)
BP control by day 21 68 (99) 65 (100) 88 (98) 88 (100)
Time to achieve disease control (days) 7.7±2.51 7.8±2.91 8.6±3.51 7.9±2.41
Deaths 19 (28) 21 (32) 41 (45) 37 (42)
Severe side effects 67 97 127 130
Cumulative dose of clobetasol propionate (g) 4352 2,8802 8792 2,8802
Relapses 35 (51) 21 (32) 32 (36) 31 (35)
BP, bullous pemphigoid.
1Mean±SD.
2Median.
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Figure 2. Event-free and disease-free survival curves of BP patients from the
study. Kaplan–Meier estimates of event-free survival, i.e., combined outcome
of death or life-threatening adverse event occurrence (a) and disease-free
survival (b) of BP patients according to treatment regimen (’ patients treated
with the mild regimen of topical corticosteroids; K patients treated with the
standard regimen).
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Grundmann-Kollmann et al., 1999; Beissert et al., 2007). It is
likely that this extremely high efficacy of high potency topical
CS is due to of both local and systemic effects, as
demonstrated by the low number of positive response to
the Cosyntropin test on day 7 or even on day 30 after
epithelialization of skin lesions. However, high potency
topical CS were more effective than oral CS in our
previous study (Joly et al., 2002) with fewer side effects, a
difference that could hardly be explained by systemic effect
alone. It is possible that the systemic absorption of topical CS
may give prolonged, though potentially lower, systemic
steroid levels.
Our results clearly demonstrate the efficacy of reduced
initial daily doses of 10–30 g of clobetasol propionate adapted
to the patient’s weight and extent of disease. The disease was
controlled by day 21 in 98% of patients treated with the mild
regimen, a result nearly identical and significantly noninferior
to that obtained with the standard regimen, whatever the
extent of BP. Mean time to achieve disease control was short
(about 8 days), with no difference between the two treatment
groups. Importantly, the outcome of BP patients with
moderate disease treated with the mild regimen was
significantly improved, whereas this improvement was not
apparent in unadjusted comparisons of overall or event-free
survival over 1 year. It was revealed by comparisons adjusted
for the two main prognostic factors of BP, age, and the
Karnofsky score through the Cox model, with an almost
twofold reduction in the risk of dying or experiencing a life-
threatening side effect during the first year of treatment. This
difference between adjusted and unadjusted comparisons is a
consequence of the older age and poorer general condition of
patients assigned to the mild regimen. Indeed, the mortality
rate in subjects aged between 80 and 90 years in France is
6.5% per year. Moreover, the standardized mortality rate of
BP patients in France and in Europe is between 20 and 30%
per year, that is, between three and four times higher than
that in the general population (Gudi et al., 2005; Joly, 2008;
Langan et al., 2008). In view of these high mortality figures,
the 2.5-year older average age of patients assigned in the mild
regimen group (83.3 vs 80.3 years) should result in a
markedly lower 1-year survival. Taken together, older age
and poorer general condition of patients assigned to the mild
treatment group may explain that the beneficial effect of the
mild regimen of topical CS was only evidenced after
adjusting for age and the Karnofsky score. This beneficial
effect was not observed in patients with extensive BP
probably because the initial doses of topical CS applied to
patients with extensive BP assigned to the mild regimen
group (20–30 g per day) were closer to those used in the
standard regimen (40 g per day) than the doses of applied to
patients with moderate BP (10–20 g per day).
The use of lower initial doses of clobetasol propionate
cream, and a shorter treatment duration led to a 70%
reduction in the cumulative doses of topical CS applied.
Indeed, although the initial doses of patients with moderate
or extensive BP assigned to the mild regimen were 20 and
30 g per day as compared with 40 g per day in patients
assigned to the standard regimen, the treatment was stopped
after only 4 months in patients assigned to the mild regimen,
instead of a progressive decrease over 12 months in patients
assigned to the standard regimen. Consistently, we observed
a significant reduction of severe treatment side effects,
especially those caused by the systemic absorption of topical
CS, such as severe insulin-dependent diabetes mellitus, and
cardiovascular disorders, favored by the applications of high
doses of topical CS over a prolonged period. It is likely that
the high rate of severe treatment side effects observed in this
study is mainly because of (1) the very old age of many
patients, (2) the inclusion of almost all consecutive cases of
BP patients seen, (3) an excellent follow-up, and (4) a
recruitment bias in this hospital-based series. Indeed, many
BP patients in good general condition and/or with a limited
disease are no longer referred to Dermatology Departments
in France. Consequently, hospitalized BP patients are
predominantly the older ones, and those with the poorest
general condition and/or the most severe disease.
We observed a higher rate of relapse especially after
treatment withdrawal by day 120 among patients treated with
the mild regimen (43%) as compared with those treated with
the standard regimen (35%) who continued to receive
substantial doses of clobetasol propionate for 8 additional
months. Interestingly, we observed a clear-cut separation of
the two curves from months 4 to 6, with then a parallel
evolution of the curves from months 6 to 12. It should be
emphasized that although very few studies in the literature
have reported the rate of relapse in BP patients, a significant
proportion of them relapse despite long-term ongoing therapy
with either topical or even oral CS (Joly et al., 2002).
Interestingly, the 35 and 43% rates of relapse observed in this
study were close to the 46% rate of relapse observed among
patients treated with 1mg kg1 per day of oral prednisone in
our previous clinical trial (Joly et al., 2002).
Overall, this study demonstrates that a mild regimen of
topical CS is as effective as the standard regimen of high
doses of topical CS for the treatment of patients with BP. The
70% reduction in the cumulative doses of CS led to a major
decrease of the cost of treatment. Moreover, it resulted in
fewer treatment side effects and yielded a twofold reduction
of the risk of death or life-threatening treatment side effects
among patients with moderate BP. The short duration of this
mild regimen should improve the acceptability, as the
consolidation phase during which CS doses are tapered lasts
only 3 months. In our opinion, the major advantages of this
mild regimen outweigh the slightly higher rate of relapses
observed. Because these relapses were mainly observed after
treatment withdrawal by month 4, we are currently evaluat-
ing the efficacy of weekly applications of topical CS vs low
doses of methotrexate as maintenance therapy.
MATERIALS AND METHODS
Study patients
Twenty-three dermatologic centers in France participated in this
prospective randomized study. The study was approved by the ethics
committee of Upper Normandy and written informed consent was
obtained from each patient. This trial was registered at www.
clinicaltrials.gov (NCT 00213421) and made in accordance with the
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Declaration of Helsinki Principles. Consecutive patients with newly
diagnosed BP were eligible for entry if the following criteria were all
met: clinical features suggestive of BP (Vaillant et al., 1998; Joly
et al., 2004); subepidermal blister on skin biopsy (Courville et al.,
2000); and linear deposits of IgG and C3 along the basement
membrane zone by direct immunofluorescence (Joly et al., 1997).
Exclusion criteria were predominant or exclusive mucosal involve-
ment, treatment with oral or topical CS, dapsone, or immunosup-
pressive drugs during the previous 6 months.
Study design
This randomized study compared two parallel groups of patients
treated with either a standard (Joly et al., 2002) or mild regimen of
topical CS. As the primary outcome was event-free survival, blinding
was not deemed necessary. Randomization between the two
regimens was stratified according to center and extent of disease
categorized as moderate (p10 new bullae appearing daily on
average during the previous 3 days) or extensive (410 new bullae
per day). Randomization was performed centrally with the use of
random numbers in permuted blocks of four within each stratum.
Patients were treated with topical applications of 0.005% clobetasol
propionate cream (Dermoval cream; Glaxo SmithKline, Philadel-
phia, PA). The standard regimen consisted of an initial dose of 40 g
per day, irrespective of the disease severity or patient weight.
Clobetasol propionate cream (20 g) was applied twice daily on the
entire body surface, until 15 days after disease control had been
attained. The doses were then reduced to 20 g daily for 1 month, 10 g
daily for 2 months, 10 g every other day for 4 months, and finally,
10 g twice a week for 4 months. Treatment was stopped after 12
months. Patients assigned to the mild regimen had their initial dose
adapted to their weight and extent of BP. Namely, patients with
extensive BP received a daily dose of 20 g of clobetasol propionate if
their weight was less than 45 kg, or 30 g if it was at least 45 kg. This
initial dose was applied until 15 days after disease control;
thereafter, the doses were reduced to 20 or 30 g every other day
for 1 month, 20–30 g twice a week for 1 month, and finally 20–30 g
once a week for 1 month, respectively. Treatment was stopped after
4 months. Patients with moderate BP received a daily dose of 10 or
20 g daily depending on whether their weight was less or at least
45 kg. Fifteen days after disease control, the initial dose was reduced
to, respectively, 10 or 20 g every other day for 1 month, twice a
week for 1 month, and once a week for 1 month, before treatment
withdrawal after 4 months.
Relapse was defined as the occurrence of at least three new
bullae daily for 3 consecutive days during the period when CS doses
were being reduced or after treatment withdrawal and/or the
occurrence of urticarial lesions, which did not disappear sponta-
neously within 3 days. For patients who experienced a relapse
during the dose reduction period, the dose was reincreased to the
previous level. Patients who experienced a relapse after treatment
withdrawal were treated using the following doses of clobetasol
propionate cream: 10 g daily for patients with a localized relapse
(that is, bullae in a single area); 20 g daily for patients with a
moderate but nonlocalized relapse (that is, at most 10 new bullae
per day in at least two separate areas); and 30 g daily for patients
with extensive relapse (that is, more than 10 new bullae per day).
Other therapy that might have affected BP activity was avoided
throughout the study period.
Baseline and follow-up measurements
The Karnofsky score was assessed at baseline. This score is a
measure of the patient’s general condition and degree of autonomy
on a scale ranging from 0 to 100, with higher scores indicating better
condition and greater autonomy (Crooks et al., 1991). The number of
new bullae that appeared daily was recorded. Because of the high
mortality reported in many recent studies during the first year after
BP diagnosis, the follow-up was limited to 12 months. At each
follow-up visit (on days 7, 14, 21, 30, 90, 120, 180, 270, and 360),
patients underwent physical examination and the number of new
bullae that appeared daily was noted, as was the number of units of
clobetasol propionate cream that had been used. If applicable, the
date of relapse was recorded, as were the date and cause of death.
Any adverse events were precisely assessed on a standardized form,
and their severity was graded 1 for mild effects, 2 for moderate
effects, 3 for severe effects, or 4 for life-threatening effects, according
to the standard criteria of the World Health Organization (WHO
Collaborating Centre for International Drug Monitoring, 1992).
Test for adrenal suppression
Plasma cortisol levels were measured at 0800hours and 2 hours after
intravenous administration of 250mg of 1–24 corticotropin (Cosyn-
tropin test) in 28 BP patients recruited in one center who received a
daily dose of clobetasol propionate cream of 20 g (n¼ 9), 30 g
(n¼ 9), or 40 g (n¼ 10). Hormone measurements were performed
before treatment (day 0), after 7 days of treatment and after
epithelialization of skin lesions on day 30. A positive response was
defined as an increase of plasma cortisol level higher than
600 nmol l1, 60minutes after the intravenous administration of
1–24 corticotropin.
Statistical analysis
The two primary end points were: (1) disease control at day 21,
defined as the absence of new bullae for 3 consecutive days and (2)
the combined outcome of death of any cause or life-threatening
adverse events (that is, event-free survival) over the 1-year follow-up.
In addition to the overall analysis, separate analyses were performed
for patients with moderate and extensive BP. Secondary end points
were: time to achieve disease control; occurrence of severe (grade 3
or 4) side effects (adverse events requiring hospitalization or
prolongation of hospitalization or life-threatening events) during
the follow-up year; occurrence of relapses during follow-up; and
cumulative doses of clobetasol propionate cream used during the
study period.
The study was designed to have 80% power to detect a 33%
reduction in the 1-year rate of deaths or life-threatening events, from
40 to 27%, with the one-sided log-rank test and a type I error of 5%.
To achieve this power, 157 patients were required in each treatment
group. For disease control at day 21, this sample size yields greater
than 95% power to detect noninferiority of the mild regimen with a
noninferiority range of 0.05 relative to 0.99 disease control rate with
the standard regimen for 0.99 expected control rate with the mild
regimen. Similarly, it yeilds greater than 90% power to detect
noninferiority of the mild regimen with a noninferiority range of 0.05
relative to 0.99 disease control rate with the standard regimen for
0.98 expected control rate with the standard regimen. Intention to
treat analyses were performed. No interim efficacy analysis was
either scheduled or performed. We checked that all the elements of
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good reporting for noninferiority studies in the revised Consolidated
Standards of Reporting Trials statement were fulfilled in this report.
Distributions of event-free, overall, and disease-free survivals
according to treatment group were estimated by the Kaplan–Meier
method and compared with the use of the log-rank test. Disease-free
survival was defined as the time from randomization to the
occurrence of the first relapse. A Cox model was used to adjust
the comparisons of event-free survival between treatment groups for
baseline characteristics that were previously demonstrated to have
prognostic significance, namely older age (483 vs p83 years) and
poor general condition as measured by the Karnofsky score (440 vs
p40; Joly et al., 2005). Exact binomial probabilities were used to
estimate 95% CIs for the rates of disease control. Noninferiority of
the mild regimen was tested with reference to 0.99 disease control
rate with the standard regimen for a 0.05 noninferiority range (that is,
down to 0.94 control rate) using a standard parametric test.
The Mann–Whitney test was used to compare times to achieve
disease control, as well as cumulative doses of clobetasol
propionate. For all tests, two-sided P-values less than 0.05 were
considered to indicate statistical significance. Continuous variables
are expressed as mean±SD. Software packages SAS version 8.02
(SAS Institute, Cary, NC) and StatXact version 7 (Cytel Software
Corporation, Cambridge, MA) were used.
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